1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies

Wedgewood Partners' David Rolfe Comments on Gilead Sciences

November 12, 2012 | About:

Gilead Sciences (NASDAQ:GILD) was among our top performers during the third quarter. We believe that the stock's strong performance over the past three months, as well as the past year is quite warranted, as the company is on the cutting edge in developing a cure for the hepatitis C virus (HCV). The Company’s journey down this path began last November with their $11 billion purchase of Pharmasset, Inc. Pharmasset’s flagship drug candidate (PSI-7977, now GS-7977) is undergoing trials indicated for all-oral treatment of HCV and if ultimately approved by the FDA, Gilead could possess a multi-year, multi-billion dollar revenue opportunity. We believe that the market, more recently, has better recognized this opportunity, so we trimmed our positions during the quarter.

From Wedgewood Partners Third Quarter 2012 Review and Outlook.


Rating: 5.0/5 (2 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by


User Generated Screeners


DBrizanROTA22nov2017 943p
pbarker4652 week
pbarker46E&P CDN
kancheesiongL30Grw1
moorebpLeveraged small-caps
kazu2016-12-15 Gori bu
mkettler0217hunting grounds
Nightdoc2Safe&Cheap&Honest
wqecapitalscreening value growth
wqecapitalscreening 1 value growth
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK